Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with two SEC-registered follow-on offerings of common stock of Atara Biotherapeutics, Inc., the first of which was for $140 million and closed on January 9, 2018, and the second of which was for $162 million and closed on March 5, 2018. The common stock is listed on the NASDAQ Global Market under the symbol “ATRA.”

Based in South San Francisco, California, Atara Bio is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Donald K. Lang, Amy Tu and Xin (Anita) Guo. The tax team included partner Rachel D. Kleinberg and associate Andrew Imber. Counsel Michelle Ontiveros Gross and associate Jason J. Bang provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post